1	Immunoglobulin G glycome composition in transition from pre-menopause to menopause		
2			
3	Domagoj Kifer ¹ , Helena Deriš ² , Ana Cindrić ² , Tea Petrović ² , Ana Cvetko ¹ , Irena Trbojević-		
4	Akmačić ² , Louise Newson ³ , Tim Spector ⁴ , Cristina Menni ⁴ , and Gordan Lauc ^{1,2}		
5			
6	1		
7	⁺ Faculty of Pharmacy and Biochemistry, University of Zagreb, Zagreb 10000, Croatia		
8	² Genos Glycoscience Research Laboratory, Zagreb 10000, Croatia		
9	³ Newson Health Menopause & Wellbeing Centre, Church Street Stratford-Upon-Avon		
10	СV37 6НВ, UК		
11	⁴ Department of Twin Research and Genetic Epidemiology, King's College London,		
12	Westminster Bridge Road, SE17EH London, UK		
13			
14			
15			

16 Abstract

17 Background

18 Glycosylation of immunoglobulin G (IgG) is an important regulator of the immune system 19 and its changes are believed to be a significant contributor to inflammaging. Gonadal 20 hormones affect IgG glycome composition, suggesting that alterations in IgG glycosylation 21 might be one of the molecular mechanisms behind increased disease risk in perimenopause.

22 Methods

IgG was isolated from 5,354 plasma samples collected from 1,940 females and 113 males at
multiple time points. IgG glycans were released, labelled with a fluorescent dye and
analysed by ultra-high-performance liquid chromatography. Mixed modelling was used to

- 26 determine average levels of individual IgG glycans in pre-menopausal women, menopausal
- 27 women, and men.
- 28 Findings

Large and statistically significant differences in IgG glycome composition were observed, mainly reflecting decreased galactosylation and sialylation of glycans in menopausal

- 31 women. During perimenopause women had a significant higher rate of increase in
- 32 agalactosylated structures (0.051/yr; 95%CI = 0.043 0.059, p<0.001), and decrease in
- digalactosylated (-0.043/yr; 95%Cl = -0.050 -0.037, p<0.001), and monosialylated glycans (-
- 34 0.029/yr; 95%CI = -0.034 -0.024, p<0.001), compared to premenopausal women.
- 35 Interpretation
- 36 Proinflammatory IgG glycome and the resulting decrease in the ability of IgG to suppress
- 37 low-grade chronic inflammation may be an important molecular mechanism mediating the
- 38 increased health risk in perimenopause. IgG glycome changes considerably during
- 39 perimenopause and may aid the diagnosis of perimenopause.
- 40 Funding
- 41 Croatian National Centre of Excellence in Personalised Healthcare, ESI Funds grant for the
- 42 Centre of Competences in Molecular Diagnostics, the Wellcome Trust and the Medical
- 43 Research Council (MRC)/British Heart Foundation (BHF).
- 44

45 Introduction

Glycosylation of immunoglobulin G (lgG) is an important regulator of the immune system 1 . 46 In addition to directly affecting the effector functions of IgG by promoting its binding to 47 different Fc receptors², glycans attached to IgG have numerous other roles in the regulation 48 of the immune system ^{3,4}. Glycans are also important mediators of the anti-inflammatory 49 activity of IgG ^{5,6} as well as the driving force for one of the molecular mechanisms underlying 50 immunosuppressive activity of intravenous IgG (IVIG) therapy used to treat a variety of 51 immunological disorders ⁷. Changes in IgG glycosylation are also believed to be an important 52 contributor to aging at the molecular level through a process called inflammaging ⁸. 53

IgG glycome composition is tightly regulated and, despite the absence of a direct genetic 54 template, is heritable to a significant extent ^{9,10}. Alternative glycosylation (the attachment of 55 different glycan structures to the same glycosylation site) is structurally and functionally 56 57 analogous to coding mutations, but instead of being defined by sequence variation in individual genes, glycome composition is inherited as a complex trait encoded by multiple 58 genes ¹¹. Genome-wide association studies identified a network of over 30 genes that 59 associate with the IgG glycome composition $^{12-14}$. One of the regulators of IgG glycosylation 60 are sex hormones, and the association between estradiol and the IgG glycome composition 61 was confirmed to be causal ¹⁵. Recent randomised placebo-controlled clinical study 62 demonstrated that the deprivation of gonadal hormones resulted in an increase of 63 biological age measured by IgG glycans, which was completely prevented by estradiol 64 65 supplementation ¹⁶.

66 Large population studies revealed that IgG glycome composition changes with age and that in females this change is particularly pronounced in the time preceding the average age of 67 menopause ^{17,18}. However, the association between changes in the IgG glycome 68 composition and menopause has not yet been validated. Perimenopause is accompanied by 69 70 different symptoms and is very often misdiagnosed due to changing hormone levels and 71 symptom overlap with other conditions. Menopause associates with an increased risk of 72 developing a range of diseases affecting metabolism, bones, cardiovascular system, brain, even cancer ¹⁹. Early perimenopause diagnosis would enable timely interventions to ease 73 the symptoms, decrease risks of developing accompanying diseases, and timely monitoring 74 of any changes in women's health status due to hormonal changes. To fill this knowledge 75 76 gap and explore the association of IgG glycome changes with perimenopause, we analysed 77 IgG N-glycome composition in 5,080 samples from 1,940 females in multiple time points 78 during their transition from pre-menopause to menopause, along with 274 samples from 79 113 males as an additional control.

80

82 Methods

83 <u>Study population</u>

Study subjects were individuals enrolled in the TwinsUK registry, a national register of adult 84 twins recruited as volunteers without selecting for any particular disease or traits ²⁰. Data on 85 menopause was gathered through the multiple choice questionare asking women at each 86 visit: "What is your menopausal status?" with possible answers "Pre menopausal", "Going 87 through the menopause", "Post menopausal" and "Don't know" and "How old were you 88 89 when you became post-menopausal (when you stopped having periods for one year or 90 more)?". Consequently sample was defined as menopausal if questionar resulted with 91 "Post-menopausal" answer or age larger then reported age of becoming postmenopausal. 92 Similarly sample was defined as premenopausal if questionare resulted with "Pre 93 menopausa" answer of age at sampleing was less then reported age of becoming 94 postmenopausal reduced by 1 year. Any inconsistent (i.e. "Pre menopausal" answer at age 95 after becoming menopausal) or unreliable data (i.e. answered as "Going through the 96 menopause") were dropped from the study (Supplementary Table 1). The TwinsUK study 97 was approved by NRES Committee London–Westminster, and all twins provided informed 98 written consent.

99

100 Isolation of IgG

IgG isolation from serum samples was performed on protein G monolithic 96-well plates as 101 previously described ²¹. In brief, 100 μ L of serum was diluted 1:7 (v/v) with PBS (phosphate 102 103 buffer saline) followed by filtration on a 0.45 µm GHP filter plate (Pall Corporation, USA). 104 Diluted and filtered serum samples were then transferred to the protein G monolithic plate, 105 which was then washed. Elution of IgG was performed with 1 mL of 0.1 mol/L formic acid 106 (Merck, Germany) followed by immediate neutralization of the mixture with ammonium 107 bicarbonate (Acros Organics, USA) to pH 7.0. IgG-containing eluate was aliquoted into PCR 108 plate (average mass of 15 μ g of IgG per sample) and dried in a vacuum centrifuge.

109

110 *Deglycosylation, labelling and purification of IgG N-glycans*

111 Deglycosylation, RapiFluor-MS labelling and purification of IgG N-glycans were performed 112 using the GlycoWorks RapiFluor-MS N-Glycan Kit obtained from Waters Corporation (USA). 113 The entire procedure was done following Waters' protocol (Waters Corporation 2017, 114 https://www.waters.com/webassets/cms/support/docs/715004793en.pdf). In the end, the 115 samples of released and labelled IgG glycans were stored at -20 °C until further use.

116

117 <u>HILIC-UHPLC-FLR analysis of RapiFlour-MS labelled IgG N-glycans</u>

118 RapiFluor-MS labelled IgG N-glycans were analysed using ultra-high-performance liquid 119 chromatography based on hydrophilic interactions with fluorescence detection (HILIC-120 UHPLC-FLR) on Waters Acquity UPLC H-class instruments. The instruments were controlled 121 and monitored with the Empower 3 software, build 3471 (Waters, USA). Chromatographic 122 separation of glycan structures was performed on Waters UPLC Glycan bridged ethylene hybrid (BEH) Amide chromatographic columns (130 Å, 1.7 μm BEH particles, 2.1x100 mm). 123 124 Solvent A was 50 mmol/L ammonium formate, pH 4.4, while solvent B was 100% LC-MS 125 grade acetonitrile. A linear gradient of 75-61.5 % acetonitrile (v/v) was used at a flow rate 126 of 0.4 mL/min over 30 minutes in a 42-minute analytical run. Each chromatogram was separated into 22 glycan peaks containing IgG glycan structures (Supplementary Figure 1.), 127 by automated integration ²² resulting in relative quantification of IgG N-glycans (total area 128

normalization). Specific N-glycan structures found in each glycan peak according to Keser et
al. ²³ are presented in Supplementary Table 2. Formulas used for the calculation of IgG
derived traits are presented in Supplementary Table 3.

132

133 <u>Statistical analysis</u>

After UHPLC analysis, each measured glycan peak was normalized by total chromatogram
area. Observed relative glycan abundances were log transformed and batch corrected using
ComBat method (R package 'sva'²⁴). After batch correction, values were back-transformed
to relative abundance and derived traits were calculated according to Supplementary Table
3.

Overlapping measured N-glycomes and information available on menopause found in
TwinsUK register, resulted in 5354 samples from 1940 females and 113 males.

For each glycan trait the effect of menopause on the abundance was estimated by mixed 141 modelling (R package 'Ime4'²⁵). Logit transformed relative abundance was used as 142 143 dependent variable and sex, menopausal status (nested within sex), age and age-144 menopausal status interaction as fixed factors, as well as family ID and individual ID (nested within family ID) as random intercepts and age as random slope. Using model, mean values 145 146 were estimated for each group and pairwise compared using t-test (post-hoc) (R package 'emmeans' ²⁶). Given multiple testing for large number of glycans, the control of false 147 148 discovery rate (FDR) was done by adjusting p values according to Benjamini-Hochberg's 149 method.

150 For the analysis of the rate of change of glycan abundances, average yearly changes were 151 calculated from two timepoints according to the formula: rate = $(logit(glycan_2) -$ 152 $\log(g|ycan_1)/(age_2 - age_1)$, where glycan is relative abundance resulted from normalized 153 chromatogram, and age is represented in years, assuming $age_2 > age_1$. Depending on 154 menopausal status in the first and second timepoint measurements were classified into 155 three categories: premenopausal (both timepoints before menopause), perimenopausal 156 (first timepoint before, and second in the menopause), and menopausal (both timepoints in 157 menopause). Mean rates were estimated by the mixed model, in which rate was dependent 158 variable, and sex, menopausal group (nested within menopausal status) and mean age 159 $(calculated as (age_2+age_1)/2)$ were set as fixed factors, as well as family ID and individual ID 160 (nested within family ID) as random intercepts. Estimated mean rates for each menopausal 161 group and males were pairwise compared using t-test (post-hoc). FDR control was done by 162 adjusting p values according to Benjamini-Hochberg's method.

163 N-glycome (observed in one timepoint) potential for diagnosis of perimenopause was analysed in a subset of women aged between 45 and 55 years by logistic regression with L1 164 165 regularization technique (R package 'caret' and 'glmnet' ^{27,28}). The subset was split into 166 training (randomly chosen one measurement per family) and test (everything else) subset. 167 The logistic model was defined with menopausal status (TRUE/FALSE) as the dependent 168 variable, and age and all directly measured glycans as independent variables. To avoid 169 overfitting, coefficients of the logistic model were estimated by 10-fold cross validation on training subset data, with hyperparameter lambda set to lambdamin. The model was tested 170 171 on test subset; results are presented by receiver operating characteristic (ROC) curve. In 172 parallel, the null model was fitted in the same way but using only age as a predictor. 173 Observed ROC curves of the two models were compared by a bootstrap test (B = 2000) (R 174 package 'pROC'²⁹).

The rate of N-glycome change (based on two timepoints) potential for diagnosis of perimenopause was analysed in a subset of women with median two-timepoint age between 45 and 55 years in the same way as diagnosis of menopause with IgG glycome analysed in one timepoint. The perimenopausal category was defined as TRUE, while others (menopausal and premenopausal) were defined as FALSE. All statistical analyses were done using R³⁰.

- 181
- 182
- 183

184 Results

185 IgG glycome composition was analysed in multiple samples from 1,940 females and 113 males from the UK registry of adult twins. The 1,087 samples from 732 individual twins (500 186 187 families) were collected prior to the onset of menopause, while 3,993 samples from 1,678 188 individual twins (969 families) were collected after the onset of menopause (Supplementary 189 Table 1). Additionally, IgG glycome was analysed in 113 men (274 samples) as an additional 190 control. A representative chromatogram with detailed structures of individual IgG glycans is 191 shown in Supplementary Figure 1. Mixed modelling was used to determine average levels of 192 individual IgG glycans in pre-menopausal women, menopausal women, and men. Large and 193 statistically significant differences were observed in multiple glycans, mainly reflecting 194 decreased galactosylation and sialylation of glycans in menopausal women (Figure 1). Levels 195 of individual IgG glycans are available in Supplementary Figure 2.

196



198 Figure 1. IgG glycome composition in premenopausal women, menopausal women, and 199 men. Mean glycan abundances (% of total IgG glycome) and corresponding 95% confidence 200 intervals were estimated from fitted mixed model with logit transformed glycan as 201 dependent variable and sex, menopausal status (nested within sex), age and age-202 menopausal status interaction as fixed factors, as well as family ID and individual ID (nested 203 within family ID) as random intercepts and age as random slope. Only adjusted post-hoc p 204 values less than 0.1 are shown. B - bisecting N-acetylglucosamine (GlcNAc), CF - core fucose, 205 G0 - agalactosylated glycans, G1 - monogalactosylated glycans, G2 - digalactosylated 206 glycans, S1 - monosialylated glycans, and S2 - disialylated glycans. 207

It is known that IgG galactosylation and sialylation decrease with age ¹⁷ thus we attempted 208 209 to evaluate whether the changes in glycans associated with the transition to menopause 210 were more extensive than the age-related changes. Since we had multiple samples from the 211 same individual, we were able to calculate the rate of change of individual IgG glycans 212 through time. A subset of women in our cohort (n = 379) entered menopause between two 213 sampling time points, thus for them, we were also able to calculate the rate of changes in 214 individual IgG glycans during the perimenopausal period. The comparison of the rate of age-215 related IgG glycome changes (when there was no change of the menopause status) with the 216 rate of IgG glycome changes during perimenopause (i.e., between time points when the 217 transition to menopause occurred) revealed statistically significant differences for a number 218 of glycans (Supplementary Figure 3). The most prominent differences in the perimenopause 219 period were the significantly larger rates of increase in the agalactosylated structures (GO) 220 and the decrease of digalactosylated (G2) and monosialylated (S1) glycans (Figure 2). During 221 perimenopause women had a significant higher rate of increase in agalactosylated 222 structures (0.051/yr; 95%CI = 0.043 - 0.059, p<0.001), and decrease in digalactosylated (-223 0.043/yr; 95%Cl = -0.050 - -0.037, p<0.001), and monosialylated glycans (-0.029/yr; 95%Cl = 224 -0.034 – -0.024, p<0.001), compared to premenopausal women.



226

Figure 2. Average yearly change of IgG glycans in females during the perimenopause period, females in pre- or post-menopause, and males. Mean yearly change in IgG glycan abundances and corresponding 95% confidence intervals were estimated from fitted mixed model with logit transformed glycan as dependent variable and sex, menopausal status (nested within sex), age and age-menopausal status interaction as fixed factors, as well as

family ID and individual ID (nested within family ID) as random intercepts and age as random slope. Only adjusted post-hoc p values less then 0.1 are shown. B - bisecting GlcNAc, CF - core fucose, GO - agalactosylated glycans, G1 - monogalactosylated glycans, G2 - digalactosylated glycans, S1 - monosialylated glycans, and S2 - disialylated glycans.

236 Using single-point measurements of IgG N-glycans we attempted to predict menopause 237 status. The lasso model was fitted with menopausal status (TRUE for those who entered 238 menopause and FALSE for all others) as dependent variable and age and all directly 239 measured IgG glycans as predictors. The model was fitted on a randomly chosen one twin 240 per family (training set) in the subset of women with a two-timepoint median age between 241 45 and 55 years. The remaining twins were used for testing the fitted model. The same train 242 and test subset model with only mean age as a predictor were used to fit and test the model 243 for comparison (Figure 3A). IgG N-glycome in combination with age measured in a single 244 timepoint has shown a good classification performance, with the AUC of 0.853 (95% Cl 245 0.823-0.880) outperforming only age as a predictor of perimenopause (AUC of 0.818, 95% CI 246 0.783-0.849).

247 Since changes in the IgG glycome composition were the most prominent in te period of 248 perimenopause, we used the rate of changes in glycans to predict whether a given women 249 already entered the period of perimenopause, or not Figure 3B). The model was fitted on a 250 randomly chosen one twin per family (training set) in the subset of women with a two-251 timepoint median age between 45 and 55 years. The remaining twins were used for testing 252 the fitted model. The addition of the information about changes in the IgG glycan levels to a 253 prediction model notably increases AUC value compared to using only age (0.694, 95% CI 254 0.637-0.751 compared to 0.507, 95% CI 0.443-0.570, respectively).

- 255
- 256



- 257
- 258
- 259

Figure 3. . Receiver operating characteristic (ROC) curves for the prediction of

261 perimenopause using IgG glycans measured in a single time point (A) and the change in IgG

262 glycan levels between the two timepoints (B). Graphs are showing area under the curve

263 (AUC) values with 95% confidence intervals.

264

265 Discussion

266 In this study we have shown the association between the period of perimenopause and the 267 extensive changes in the IgG glycome composition. Aging continuously associates with the 268 transition of the IgG glycome from an inflammation-suppressive to a proinflammatory 269 composition, but this change is much faster in the period when women are progressing 270 from a regular cycle to menopause. The depletion of estrogen during perimenopause and 271 menopause is an important event of aging since low hormone levels increase vulnerability 272 to diseases in hormone-responsive tissues, including the brain, bone, and the cardiovascular 273 system. Menopause is therefore more complex than just being a natural condition resulting 274 in symptoms; it needs to be considered as a long-term hormone deficiency leading to health 275 risks if not appropriately managed with lifestyle adjustments or hormone replacement therapy (HRT)³¹. After entering menopause, there is an increased risk of developing obesity 276 and metabolic disease, cardiovascular diseases, osteoporosis and arthritis, dementia and 277 cognitive decline, and cancer¹⁹. 278

279 Previous population studies revealed that IgG N-glycome composition changes with age, especially in females in the time preceding the average age of menopause ^{17,18}. In this study 280 we used multiple samples from the same individuals to confirm the association between 281 282 perimenopause and the extensive changes in the IgG glycome composition. The most 283 extensive change in the IgG glycome during perimenopause was a decrease in 284 galactosylation and sialylation, a change that is generally associated with aging ¹. Aging continuously associates with the transition of the IgG N-glycome from an inflammation-285 286 suppressive to a proinflammatory composition, but this change is much faster in the period 287 when women are progressing from a regular cycle to menopause.

288 The age-related gradual decrease in the level of galactosylated IgG and the build-up of agalactosylated IgG is known to exacerbate low-grade chronic inflammation ³²⁻³⁴ and acts as 289 an effector of pro-inflammatory pathological changes ^{35,36}. Decreased levels of IgG 290 291 galactosylation and/or sialylation have been associated with a wide range of autoimmune 292 conditions, such as systemic lupus erythematosus, inflammatory bowel disease, and many 293 others. Changes in these IgG glycosylation traits are also associated with disease progression, disease activity, symptom severity, and response to treatment. In many cases, 294 295 these changes occur before the onset of symptoms ³⁷.

296

297 The rate of change from "young" to "old" IgG glycome increased significantly in the 298 perimenopausal period, suggesting that the loss of immunosuppressive functions of IgG may 299 be an underlying molecular mediator of at least some health risks in this period. The results 300 of this study also indicate the potential of the IgG glycome composition as a biomarker for 301 perimenopause. Perimenopause can last up to 15 years and is difficult to diagnose due to highly irregular hormonal cycles ³⁸. As a result of poor awareness and inappropriate use of 302 303 hormonal tests, women are often misdiagnosed with conditions such as fibromyalgia, 304 migraines, depression, or chronic fatigue syndrome and are frequently prescribed 305 antidepressants despite there being no evidence to support their use to improve the low mood associated with perimenopause or menopause ³⁹. The importance of early diagnosis 306 307 of perimenopause is supported by the research which has shown that early use of HRT leads 308 to a greater reduction of future disease incidence as well as minimising the duration of 309 symptoms ⁴⁰.

310

Recent placebo-controlled randomised trials indicated the importance of estrogens in the 311 regulation of IgG glycosylation ^{15,41}, thus it seems quite probable that the decrease in 312 estrogen levels is an important driver of changes in IgG glycosylation in primenopause. 313 Contrary to estrogens that have a very short half-life in circulation, IgG has a half-life of 314 three weeks ⁴², which implies that the current composition of the IgG glycome is affected by 315 316 average concentrations of estrogen in the past 3-4 weeks. Since changes in the IgG glycome 317 during perimenopause are so extensive, they could potentially be used as a diagnostic tool. 318 In fact, IgG glycome composition could be used to determine long-term average 319 concentrations of sex hormones in the same way glycated hemoglobin (HbA1c) is used to 320 determine long-term concentrations of blood glucose.

321

322 Limitations of the study

323 The main limitation of this study is relatively long time between individual sampling time 324 points (6.9±2.6 years) that was not tailored for the occurrence of menopause. Therefore, in 325 some cases, perimenopause was just a short part of the period in which the change in the 326 IgG N-glycome occurred, while in others sampling might have occurred within the 327 perimenopause period, with part of the perimenopause being before and another part after 328 a specific sampling. Hopefully, a future study that would have more frequent sampling 329 during the perimenopause period would enable an even more accurate assessment of IgG 330 glycome association with perimenopause.

331

332 Conclusions

Changes in IgG glycosylation from "young" to "old" glycome associate with many health risks that accompany menopause ¹. In some diseases like rheumatoid arthritis ^{43,44} and cardiovascular diseases ^{45,46} this change was shown to occur years before disease onset, suggesting the causal role of IgG glycans in disease development. Proinflammatory IgG glycome and the resulting decrease in the ability of IgG to suppress low-grade chronic inflammation may be an important molecular mechanism that mediates the increased health risk in perimenopause, thus this topic should be studied in more detail.

340 **Competing interests**

A patent covering all the main aspects of the use of IgG glycome as a predictor of menopause and perimenopause has been filed by Genos Ltd (application number: P20210509A). The application is currently pending. D.K., C.M., and G.L. are named as coinventors on the patent application. G.L. is the founder and owner of Genos Ltd, a biotech company specialising in high-throughput glycomics that also has several patents in the field. H.D., A.Ci. T.P., and I.T.-A. are employees of Genos Ltd. The remaining authors declare no competing interests.

348

349 Acknowledgements

350 This study has been supported by the Croatian National Centre of Excellence in Personalised 351 Healthcare (Contract no. KK.01.1.1.01.0010), ESI Funds grant for the Centre of Competences 352 in Molecular Diagnostics and the Human Glycome Project. Equipment and products from 353 Waters and New England Biolabs were used for this research. The Department of Twin 354 Research receives support from grants from the Wellcome Trust (212904/Z/18/Z) and the 355 Medical Research Council (MRC)/British Heart Foundation (BHF) Ancestry and Biological 356 Informative Markers for Stratification of Hypertension (AIM-HY; MR/M016560/1), European 357 Union, Chronic Disease Research Foundation (CDRF), Zoe Global Ltd., the NIHR Clinical 358 Research Facility and Biomedical Research Centre (based at Guy's and St Thomas' NHS 359 Foundation Trust in partnership with King's College London). C.M. is funded by the Chronic 360 Disease Research Foundation and by the MRC AIM-HY project grant. 361

363 References

364		
365	1	Martinić Kavur M, Lauc G, Pezer M. Systems Glycobiology: Immunoglobulin G Glycans
366		as Biomarkers and Functional Effectors in Aging and Diseases. In: Reference Module
367		in Chemistry, Molecular Sciences and Chemical Engineering. Elsevier, 2021.
368		DOI:10.1016/b978-0-12-819475-1.00086-9.
369	2	Nimmerjahn F, Ravetch J V. Fcgamma receptors as regulators of immune responses.
370		Nat Rev Immunol 2008; 8 : 34–47.
371	3	Seeling M, Brückner C, Nimmerjahn F. Differential antibody glycosylation in
372		autoimmunity: Sweet biomarker or modulator of disease activity? Nat Rev Rheumatol
373		2017; 13 : 621–30.
374	4	Ipsen-Escobedo A, Nimmerjahn F. More Rules, Still Exceptions: Understanding
375		Immunomodulatory Antibody Activity In Vivo. <i>Cancer Cell</i> 2018; 33 : 545–6.
376	5	Schwab I, Nimmerjahn F. Intravenous immunoglobulin therapy: how does IgG
377		modulate the immune system? <i>Nat Rev Immunol</i> 2013; 13 : 176–89.
378	6	Karsten CM, Pandey MK, Figge J, et al. Anti-inflammatory activity of IgG1 mediated by
379		Fc galactosylation and association of FcgammaRIIB and dectin-1. Nat Med 2012; 18:
380		1401–6.
381	7	Nimmerjahn F, Ravetch J V. Anti-inflammatory actions of intravenous
382		immunoglobulin. <i>Annu Rev Immunol</i> 2008; 26 : 513–33.
383	8	Franceschi C, Garagnani P, Parini P, Giuliani C, Santoro A. Inflammaging: a new
384		immune–metabolic viewpoint for age-related diseases. Nat. Rev. Endocrinol. 2018;
385		14 : 576–90.
386	9	Pučić M, Knežević A, Vidič J, et al. High throughput isolation and glycosylation analysis
387		of IgG-variability and heritability of the IgG glycome in three isolated human
388		populations. <i>Mol Cell Proteomics</i> 2011; 10 : M111.010090.
389	10	Menni C, Keser T, Mangino M, <i>et al</i> . Glycosylation of immunoglobulin G: Role of
390		genetic and epigenetic influences. <i>PLoS One</i> 2013; 8 .
391		DOI:10.1371/journal.pone.0082558.
392	11	Krištić J, Zaytseva OO, Ram R, <i>et al</i> . Profiling and genetic control of the murine
393		immunoglobulin G glycome. <i>Nat Chem Biol</i> 2018; 14 : 516–24.
394	12	Shen X, Klarić L, Sharapov S, et al. Multivariate discovery and replication of five novel
395		loci associated with Immunoglobulin G N-glycosylation. <i>Nat Commun</i> 2017; 8 .
396		DOI:10.1038/s41467-017-00453-3.
397	13	Klaric L, Tsepilov YA, Stanton CM, et al. Glycosylation of immunoglobulin G is
398		regulated by a large network of genes pleiotropic with inflammatory diseases. <i>Sci Adv</i>
399		2020; 6 . DOI:10.1126/sciadv.aax0301.
400	14	Lauc G, Huffman JE, Pučić M, <i>et al</i> . Loci Associated with N-Glycosylation of Human
401		Immunoglobulin G Show Pleiotropy with Autoimmune Diseases and Haematological
402		Cancers. PLoS Genet 2013; 9 . DOI:10.1371/journal.pgen.1003225.
403	15	Ercan A, Kohrt WM, Cui J, <i>et al</i> . Estrogens regulate glycosylation of IgG in women and
404		men. <i>JCI Insight</i> 2017; 2 . DOI:10.1172/jci.insight.89703.
405	16	Juric J, Kohrt WM, Kifer D, et al. Effects of estradiol on biological age measured using
406		the glycan age index. AGING-US 2020; 12 : 19756–65.
407	17	Krištić J, Vučković F, Menni C, <i>et al</i> . Glycans are a novel biomarker of chronological
408		and biological ages. <i>Journals Gerontol - Ser A Biol Sci Med Sci</i> 2014; 69 : 779–89.
409	18	Stambuk J, Nakic N, Vuckovic F, <i>et al.</i> Global variability of the human IgG glycome.

44.0		ACING 46 2020 42 45222 50
410	4.0	AGING-US 2020; 12: 15222–59.
411	19	Lobo RA, Davis SR, De Villiers TJ, <i>et al.</i> Prevention of diseases after menopause.
412		<i>Climacteric</i> 2014; 17 : 540–56.
413	20	Verdi S, Abbasian G, Bowyer RCE, <i>et al.</i> TwinsUK: The UK Adult Twin Registry Update.
414		Twin Res Hum Genet 2019; 22 : 523–9.
415	21	Trbojević-Akmačić I, Ugrina I, Lauc G. Comparative Analysis and Validation of
416		Different Steps in Glycomics Studies. <i>Methods Enzymol</i> 2017; 586 : 37–55.
417	22	Agakova A, Vučković F, Klarić L, Lauc G, Agakov F. Automated integration of a UPLC
418		glycomic profile. 2017 DOI:10.1007/978-1-4939-6493-2_17.
419	23	Keser T, Pavic T, Lauc G, Gornik O. Comparison of 2-aminobenzamide, procainamide
420		and RapiFluor-MS as derivatizing agents for high-throughput HILIC-UPLC-FLR-MS N-
421		glycan analysis. Front Chem 2018; 6. DOI:10.3389/fchem.2018.00324.
422	24	Leek JT, Johnson WE, Parker HS, Jaffe AE, Storey JD. The sva package for removing
423		batch effects and other unwanted variation in high-throughput experiments.
424		Bioinformatics 2012; 28 : 882–3.
425	25	Bates D, Mächler M, Bolker B, Walker S. Fitting Linear Mixed-Effects Models Using
426		lme4. <i>J Stat Softw</i> 2015; 67 . DOI:10.18637/jss.v067.i01.
427	26	Lenth R. emmeans: Estimated Marginal Means, aka Least-Squares Means. 2020.
428	27	Friedman J, Hastie T, Tibshirani R. Regularization paths for generalized linear models
429		via coordinate descent. <i>J Stat Softw</i> 2010; 33 .
430	28	Kuhn M. caret: Classification and Regression Training. 2020.
431	29	Robin X, Turck N, Hainard A, et al. pROC: an open-source package for R and S+ to
432		analyze and compare ROC curves. BMC Bioinformatics 2011; 12: 77.
433	30	R Core Team, Team RDC, R Core Team. R: A Language and Environment for Statistical
434		Computing. 2020.
435	31	Gambacciani M, Cagnacci A, Lello S. Hormone replacement therapy and prevention of
436		chronic conditions. Climacteric. 2019; 22 : 303–6.
437	32	Franceschi C, Bonafe M, Valensin S, et al. Inflamm-aging. An evolutionary perspective
438		on immunosenescence. Ann N Y Acad Sci 2000; 908 : 244–54.
439	33	De Martinis M, Franceschi C, Monti D, Ginaldi L. Inflamm-ageing and lifelong antigenic
440		load as major determinants of ageing rate and longevity. FEBS Lett 2005; 579: 2035-
441		9.
442	34	Monti D, Ostan R, Borelli V, Castellani G, Franceschi C. Inflammaging and human
443		longevity in the omics era. <i>Mech Ageing Dev</i> 2017; 165 : 129–38.
444	35	Franceschi C, Capri M, Monti D, <i>et al</i> . Inflammaging and anti-inflammaging: A
445		systemic perspective on aging and longevity emerged from studies in humans. <i>Mech</i>
446		Ageing Dev 2007; 128 : 92–105.
447	36	Dall'Olio F, Vanhooren V, Chen CC, Slagboom PE, Wuhrer M, Franceschi C. N-glycomic
448		biomarkers of biological aging and longevity: A link with inflammaging. Ageing Res
449		<i>Rev</i> 2013; 12 : 685–98.
450	37	Gudelj I, Lauc G, Pezer M. Immunoglobulin G glycosylation in aging and diseases. <i>Cell</i>
451		Immunol 2018; 333 : 65–79.
452	38	National Institute for Health and Care Excellence. Menopause: Diagnosis and
453		Management. Nice 2015.
454	39	Leonhardt M. Low mood and depressive symptoms during perimenopause – Should
455		General Practitioners prescribe hormone replacement therapy or antidepressants as
456		the first-line treatment? <i>Post Reprod Heal</i> 2019; 25 : 124–30.

457 458	40	Ward K, Deneris A. An Update on Menopause Management. J. Midwifery Women's Heal. 2018; 63 : 168–77.
459 460	41	Jurić J, Kohrt WM, Kifer D, <i>et al.</i> Effects of estradiol on biological age measured using the glycan age index. <i>Aging (Albany NY)</i> 2020; 12 : 19756–65.
461 462	42	Vidarsson G, Dekkers G, Rispens T. IgG subclasses and allotypes: From structure to effector functions. <i>Front Immunol</i> 2014: 5 . DOI:10.3389/fimmu.2014.00520.
463 464 465	43	Gudelj I, Salo PP, Trbojević-Akmačić I, <i>et al.</i> Low galactosylation of IgG associates with higher risk for future diagnosis of rheumatoid arthritis during 102 years of follow-up. <i>Biochim Biophys Acta - Mol Basis Dis</i> 2018. DOI:10.1016/i.bbadis.2018.03.018.
466 467 468	44	Ercan A, Cui J, Chatterton DE, <i>et al.</i> Aberrant IgG galactosylation precedes disease onset, correlates with disease activity, and is prevalent in autoantibodies in rheumatoid arthritis. <i>Arthritis Rheum</i> 2010; 62 : 2239–48.
469 470 471 472	45	Menni C, Gudelj I, MacDonald-Dunlop E, <i>et al.</i> Glycosylation Profile of Immunoglobulin G Is Cross-Sectionally Associated with Cardiovascular Disease Risk Score and Subclinical Atherosclerosis in Two Independent Cohorts. <i>Circ Res</i> 2018; 122 : 1555–64.
473 474 475 476 477	46	Wittenbecher C, Štambuk T, Kuxhaus O, <i>et al.</i> Plasma N-glycans as emerging biomarkers of cardiometabolic risk: A prospective investigation in the EPIC-Potsdam cohort study. <i>Diabetes Care</i> 2020; 43 : 661–8.

479 Supplementary Tables and Figures

	Samples	Individuals	Families
Count, N	5354	2053	1173
- by sex (%)			
Male	274 (5)	113 (6)	69 (6)
Female	5080 (95)	1940 (94)	1104 (94)
- by group (%)		, ,	,
Pre-menopause	1087 (21)	732	500
Menopause	3993 (79)	1678	969
·			
- by age subset (%)			
Between 45 and 55 years	1374 (26)	1065 (52)	670 (57)
- by sex (%)			
Male	87 (6)	59 (6)	39 (6)
Female	1287 (94)	1006 (94)	631 (94)
- by group (%)			
Pre-menopause	507 (39)	453	340
Menopause	780 (61)	662	458
- by number of samples (%)			
One		203 (10)	
Тwo		399 (19)	
Three		1451 (71)	
Age in years, mean (SD)	58.3 (11.3)	57.6 (10.3)	57.2 (10.3
- by sex			
Male	57.9 (11.7)	57.4 (10.8)	57.4 (10.9
Female	58.3 (11.2)	57.6 (10.3)	57.2 (10.3
- by group			
Pre-menopause	43.1 (7.1)	44.0 (6.0)	44.6 (5.9
Menopause	62.4 (8.2)	61.7 (6.6)	61.3 (6.7
- by age subset			
Between 45 and 55 years	50.6 (3.1)	50.7 (2.6)	50.6 (2.6
- by sex			
Male	50.5 (3.1)	50.6 (2.6)	50.6 (2.5
Female	50.6 (3.1)	50.7 (2.6)	50.6 (2.6
- by group			
Pre-menopause	48.5 (2.6)	48.5 (2.4)	48.7 (2.4
Menopause	51.9 (2.7)	52.2 (2.3)	52.0 (2.2
Follow up time in years, mean (SD)			
between consecutive samples		6.94 (2.58)	
- by sex			
Male		7.17 (2.94)	
Female		6.93 (2.56)	
total follow up time		12.2 (4.3)	
- by sex			
Male		12.1 (4.8)	
Female		12.2 (4.3)	

480 **Supplementary Table 1.** Descriptive information about the cohort

482 **Supplementary Table 2.** Detailed description of glycan structures according to Keser et al.²³

483	corresponding to ev	erv individual immun	oglobulin Rar	piFluor-MS glycan	peak.*
100					peon

RapiFluor-MS glycan peak	Glycan structure	Description	Formula
GP1	FA1	core fucosylated, monoantennary	GP1/GP
GP2	A2	agalactosylated, biantennary	GP2 / GP
GP3	FA2; A2B	core fucosylated, biantennary (major); biantennary with bisecting GlcNAc (minor)	GP3 / GP
GP4	FA2B; M5	core fucosylated, biantennary with bisecting GlcNAc (major); oligomannose (minor)	GP4 / GP
GP5	A2[6]G1	monogalactosylated, biantennary	GP5 / GP
GP6	A2[3]G1	monogalactosylated, biantennary	GP6 / GP
GP7	FA2[6]G1	core fucosylated and monogalactosylated, biantennary	GP7 / GP
GP8	FA2[3]G1	core fucosylated and monogalactosylated, biantennary	GP8 / GP
GP9	FA2[6]BG1	core fucosylated and monogalactosylated, biantennary with bisecting GlcNAc	GP9/GP
GP10	FA2[3]BG1	core fucosylated and monogalactosylated, biantennary with bisecting GlcNAc	GP10 / GP
GP11	A2G2	digalactosylated, biantennary	GP11 / GP
GP12	FA2G2; A2BG2	core fucosylated, digalactosylated, biantennary (major); digalactosylated, biantennary with bisecting GlcNAc (minor)	GP12 / GP
GP13	FA2BG2	core fucosylated, digalactosylated, biantennary with bisecting GlcNAc	GP13 / GP
GP14	FA2[6]G1S1; FA2[3]G1S1	core fucosylated, monogalactosylated and monosialylated biantennary; core fucosylated, monogalactosylated and monosialylated biantennary	GP14 / GP
GP15	A2G2S1	digalactosylated and monosialylated biantennary	GP15 / GP
GP16	FA2G2S1	core fucosylated, digalactosylated and monosialylated biantennary	GP16 / GP
GP17	FA2BG2S1	core fucosylated, digalactosylated and monosialylated biantennary with bisecting GlcNAc	GP17 / GP
GP18	n.d.	structure not determined	GP18 / GP
GP19	A2G2S2	digalactosylated and disialylated biantennary	GP19/GP
GP20	A2BG2S2	digalactosylated and disialylated biantennary with bisecting GlcNAc	GP20 / GP
GP21	FA2G2S2	core fucosylated, digalactosylated and disialylated GP21 / GP	
GP22	FA2BG2S2	core fucosylated, digalactosylated and disialylated biantennary with bisecting GlcNAc	GP22 / GP

484 *structure abbreviations – all N-glycans have two core N-acetylglucosamines (GlcNAcs); F at

the start of the abbreviation indicates a core-fucose α 1,6-linked to the inner GlcNAc; Mx,

486 number (x) of mannose on core GlcNAcs; Ax, number of antenna (GlcNAc) on trimannosyl

487 core; A2, biantennary with both GlcNAcs as β 1,2-linked; B, bisecting GlcNAc linked β 1,4 to

488 β1,3 mannose; G(x), number (x) of β1,4 linked galactose on antenna; S(x), number (x) of

489 sialic acids linked to galactose

Supplementary Table 3 Formulas used for the calculation of IgG derived traits

Structural feature	Formula
Agalactosylation (G0)	GP1+GP2+GP3+GP4
Monogalactosylation (G1)	GP5+GP6+GP7+GP8+GP9
Digalactosylation (G2)	GP10+GP11+GP12+GP13
Monosialylation (S1)	GP14+GP15+GP16+GP17
Disialylation (S2)	GP19+GP20+GP21+GP22
Incidence of bisecting GlcNAc (B)	GP4+GP9+GP10+GP13+GP17+GP20+GP22
Core fucosylation (CF)	GP1+GP3+GP4+GP7+GP8+GP9+GP10+GP12+GP13+GP14+GP16+GP17+GP21+GP22







Supplementary Figure 2. IgG glycome composition in premenopausal and menopausal women, and men. Mean glycan abundances (% of total IgG N-glycome) and corresponding 95% confidence intervals were estimated from fitted mixed model with logit transformed glycan as dependent variable and sex, menopausal status (nested within sex), age and age-menopausal status interaction as fixed factors, as well as family ID and individual ID (nested within family ID) as random intercepts and age as random slope. Only adjusted post-hoc p values less then 0.1 are shown.



Supplementary Figure 3. Average annual change of IgG glycans in females during the perimenopause period, females in pre- or post-menopause, and males. Mean yearly change in glycan abundances and corresponding 95% confidence intervals were estimated from fitted mixed model with logit transformed glycan as dependent variable and sex, menopausal status (nested within sex), age and age-menopausal status interaction as fixed factors, as well as family ID and individual ID (nested within family ID) as random intercepts and age as random slope. Only adjusted post-hoc p values less then 0.1 are shown.